Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37 results about "Mental nerve" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Mental nerve is a sensory nerve which provides sensation to the front of the chin and lower lip as well as the labial gingivae of the mandibular anterior teeth and the premolars. It is a branch of the posterior trunk of the inferior alveolar nerve, which is itself a branch of the mandibular division of the trigeminal nerve (CN V).
Nutritional supplements for healthy memory and mental function
InactiveUS20080213401A1Optimizing mental energyImprove mental functionBiocideNervous disorderMental functionsMental nerve
Owner:APPLIED COGNITIVE SCI
Chemokine receptor antagonists and use thereof
InactiveUS8168783B2Prevention and therapyBiocideSenses disorderArterial Occlusive DiseasesMental nerve
Owner:ONO PHARMA CO LTD
Mobile phone for stimulating the trigeminal nerve to treat disorders
ActiveUS20140330336A1Avoid stimulationMaximum effectivenessElectrotherapyDevices with sensorDiseaseMental nerve
Devices and methods are disclosed that allow a patient to self-treat a medical condition, such as migraine headache and trigeminal neuralgia and the like, by noninvasive electrical stimulation of nerves of the head, particularly supraorbital, supratrochlear, infraorbital, and mental nerves in the vicinity of their foramen or notch. The system comprises a handheld mobile device, such as a smartphone, that is applied to the surface of the patient's head. One or more electrodes on the mobile device apply electrical impulses transcutaneously through the patient's skin to the targeted nerve to treat the medical condition. The system is designed to address problems that arise particularly during self-treatment, when a medical professional is not present.
Owner:ELECTROCORE
Compound having acidic group which may be protected, and use thereof
A compound represented by general formula (I):a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification. The compound of the present invention has antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.
Owner:ONO PHARMA CO LTD
Compound containing basic group and use thereof
Owner:ONO PHARMA CO LTD
Methods for regulating neurotransmitter systems by inducing counteradaptations
The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to period between administrations of no greater than ½. The methods of the present invention may be used to address a whole host of undesirable mental, neurological and physiological conditions.
Owner:MICHALOW ALEXANDER
Compound containing basic group and use thereof
Owner:ONO PHARMA CO LTD
Traditional Chinese medicine composition with estrogen-like action and use thereof
InactiveCN101396421AIt has two-way regulationImprove side effectsSexual disorderPlant ingredientsVasomotor symptomDisease
The invention relates to a composition with the plant estrogen-like effects, and the composition is prepared by the following pharmaceutical raw materials by weight percentage: 12-64 percent eucommia bark and 6-38 percent malaytea scurfpea fruit. The traditional Chinese medicine composition has the plant estrogen-like effects and can bi-directionally regulate the estrogen level of human body, delay the arrival of menopause and be applicable to improving the perimenopausal syndrome of women: menstrual disorders, vasomotor symptoms (flushes and hot flushes), mental and neurological disorders (depression, anxiety, excitability and insomnia), cardiovascular and cerebrovascular symptoms (hypertension, hyperlipidemia, heart palpitations, atherosclerosis, coronary heart disease, senile dementia, and the like), bone and joint symptoms (osteoporosis, arthralgia, and the like), symptoms of urogenital tract and other diseases.
Owner:SHANGHAI UNIV OF T C M
Nutritional supplements for healthy memory and mental function
InactiveUS7972633B2Function increaseImprove performanceCosmetic preparationsBiocideMental functionsMental nerve
Owner:APPLIED COGNITIVE SCI
Therapeutic agent for psychoneurotic disease
The present invention relates to a preventive and / or therapeutic agent for psychoneurotic diseases, comprising an EP3 antagonist represented by the general formula (I):(wherein the meanings of characters are defined in the description). This compound has an antagonistic potency against EP3 and exhibits efficacy through unusual action mechanism as a preventive and / or therapeutic agent for psychoneurotic disorder, psychosomatic disorder, anxiety disorder, depression and disorder caused by stress.
Owner:ONO PHARMA CO LTD
Remedy For Psychoneurotic Diseases
InactiveUS20080103166A1Effective preventionEffective treatmentBiocideNervous disorderDiseaseMental nerve
A medicinal preparation for preventing and / or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.
Owner:CHIBA UNIVERSITY
Remedies for psychoneurosis
A therapeutic drug for psychoneurotic disorders, which is useful for therapies of psychoneurotic disorders, especially restless legs syndrome is disclosed. The therapeutic drug for psychoneurotic disorders according to the present invention comprises as an effective ingredient an opioid κ receptor agonist compound (excluding pentazocine) such as (−)-17-(cyclopropylmethyl)-3,14β-dihydroxy-4,5α-epoxy-6β[N-methyl-trans-3-(3-furyl)acrylamide]morphinan hydrochloric acid salt.
Owner:TORAY IND INC
Mentation test method and mentation test apparatus
InactiveUS6875181B2Quick switchThe degree of freedom becomes largerSurgeryVaccination/ovulation diagnosticsSequelaMental testing
A mentation test method that can test mentation of a human such as conjecture of brain's mentation age, discrimination of early stage of dementia and prediction of onset of dementia in addition to diagnosis of prediction probability of onset of dementia and screening of mental functions of senile dementia patients, decision of the effect of rehabilitation of the aftereffects of cerebrovascular disfunction, investigation of the therapeutic effects of medicines and side effects such as sleepiness, testing of degree of intoxication, testing of peripheral attention visual field, testing of cerebral dominant hemisphere, testing of various psychoneurosis such as schizophrenia and cerebrovascular disorder (syndrome and diagnosis, and decision of the effects of rehabilitation and treatment), and check of the degree of fatigue.
Owner:KABUSHIKIGAISHA SOGO IKAGAKU KENKYUSYO
Antipruritics
The present invention relates to an antipruritic agent comprising a nociceptin antagonist as an active ingredient. The nociceptin antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney dialysis, diabetes, blood disease, liver disease, kidney disease, incretion and metabolic disorder, viscera malignant tumor, hyperthyroidism, autoimmune disease, multiple sclerosis, neurologic disease, psychoneurosis, allergic conjunctivitis, spring catarrh, atopic keratoconjunctivitis, or itching caused by excess use of laxuries and drugs because it has excellent scrtaching behavior suppressing effect, that is, antiitching effect and antipruritic effect.
Owner:NIPPON SHINYAKU CO LTD
Compound having cyclic group bound thereto through spiro binding and use thereof
InactiveUS20090325992A1Prevention and therapyTreatment safetyAntibacterial agentsBiocideDiseaseMental nerve
A compound represented by general formula (I):a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and / or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.
Owner:ONO PHARMA CO LTD
Composition containing fish eyes, theanine and gamma-aminobutyric acid and capable of alleviating asthenopia
InactiveCN108354175AImprove neurological symptomsSignificant effect in alleviating visual fatigueSenses disorderDough treatmentMental nerveGamma-Aminobutyric acid
The invention relates to a composition containing fish eyes, theanine and gamma-aminobutyric acid and capable of alleviating asthenopia, belongs to the field of medicine health, and provides a composition capable of alleviating asthenopia. The active components of the composition comprise fish eyeball tissues or an extract thereof, fish eye socket tissues and an extract thereof, the theanine and the gamma-aminobutyric acid. Test results in crowds prove that the composition has effect on eye local symptoms of asthenopia, can obviously improve the neurosis symptoms caused by asthenopia of different degrees, such as unconcentrated attention, and reduced memory, is notable in effect of alleviating asthenopia and has broad market development prospect.
Owner:成都图径生物科技有限公司
Compound with phosphodiesterase 4D and acid sphingomyelinase inhibitory activity
ActiveCN110305072AStrong inhibitory activityNervous disorderOrganic chemistryPhosphodiesteraseMental nerve
The invention discloses a compound with phosphodiesterase 4D and acid sphingomyelinase inhibitory activity. The compound has good PDE4D / ASM double-target inhibitory activity and can be used for preventing and / or treating diseases associated with the phosphodiesterase 4D and the acid sphingomyelinase, and the diseases particularly include inflammatory diseases, autoimmune diseases such as dermatitis, atopic dermatitis, psoriasis and multiple sclerosis, cardiovascular diseases such as atherosclerosis and ischemia reperfusion injury, hepatic diseases such as non-alcoholic steatohepatitis, alcoholic steatohepatitis and hepatic fibrosis, mental and neurological diseases such as depression and anxiety disorder, neurodegenerative diseases such as Alzheimer's diseases, respiratory system diseasessuch as chronic obstructive pulmonary diseases, cystic fibrosis, pulmonary fibrosis, pulmonary edema and lung injury and metabolic diseases such as diabetes.
Owner:CHINA PHARM UNIV
Soy Milk Made From Germinated Soy Beans
InactiveUS20100119689A1Acidic food ingredientsFood ingredient functionsMental nerveMenopausal disorders
Soymilk is provided which can prevent or alleviate menopausal disorders, and is highly safe with no risk of side effects even with long-term intake thereof. This soymilk is made from germinated soybeans, and is used for alleviating or preventing the vasomotor disorder-like symptoms and psychoneuropathic disorder-like symptoms associated with menopausal disorders. Furthermore, this soymilk is labeled with a notice specifying that the soymilk is to be used for alleviating or preventing the vasomotor disorder-like symptoms and psychoneuropathic disorder-like symptoms of menopausal disorders.
Owner:THE NISSHIN OILLIO GRP LTD
Compound containing basic group and use thereof
InactiveUS20090118279A1Preventive therapeuticAvoid prolonged useBiocideSenses disorderMental nerveArthritis
The present invention relates to a compound represented by formula (I):wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof.The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.
Owner:ONO PHARMA CO LTD
Composition containing fish eyes, theanine and phosphatidylserine for relieving visual fatigue
InactiveCN108185427AImprove neurological symptomsSignificant effect in alleviating visual fatigueSenses disorderHydroxy compound active ingredientsMental nerveEye straining
The invention relates to a composition containing fish eyes, theanine and phosphatidylserine for relieving visual fatigue, and belongs to the field of medicines and health. The invention provides a composition for relieving visual fatigue. The active ingredients of the composition comprise fish eyeball tissue or an extract thereof, fish eye socket tissue or an extract thereof, theanine and phosphatidylserine. The trial results of crowds show that the composition disclosed by the invention not only aims at the local symptoms of eyes having visual fatigue, but also can significantly improve neuropsychological syndromes caused by different degrees of visual fatigue, such as inattention, memory deterioration, and the composition is notable in the effect of relieving the visual fatigue, and hasbroad market prospects.
Owner:成都图径生物科技有限公司
Soy milk made from germinated soy beans
InactiveUS20070092588A1Alleviating and preventing symptomImprove the quality of lifeBiocideAcidic food ingredientsMental nerveSide effect
Soymilk is provided which can prevent or alleviate menopausal disorders, and is highly safe with no risk of side effects even with long-term intake thereof. This soymilk is made from germinated soybeans, and is used for alleviating or preventing the vasomotor disorder-like symptoms and psychoneuropathic disorder-like symptoms associated with menopausal disorders. Furthermore, this soymilk is labeled with a notice specifying that the soymilk is to be used for alleviating or preventing the vasomotor disorder-like symptoms and psychoneuropathic disorder-like symptoms of menopausal disorders.
Owner:THE NISSHIN OILLIO GRP LTD
Theanine, [gamma]-aminobutyric acid and anthocyanin containing composition for relieving visual fatigue
InactiveCN108324705AImprove neurological symptomsSignificant effect in alleviating visual fatigueSenses disorderNervous disorderMental nerveMedicine
The invention relates to a theanine, [gamma]-aminobutyric acid and anthocyanin containing composition for relieving visual fatigue, and belongs to the field of medical health. According to the composition for relieving the visual fatigue provided by the invention, active ingredients include theanine, [gamma]-aminobutyric acid and anthocyanin. Based upon trial results on people, it is indicated that the composition not only can relieve local symptoms of eyes having the visual fatigue but also can obviously improve psychoneural symptoms, such as attention-deficit disorder, memory loss and the like, caused by visual fatigue of different degrees; and the composition is obvious in effect of relieving the visual fatigue and has a broad market prospect.
![Theanine, [gamma]-aminobutyric acid and anthocyanin containing composition for relieving visual fatigue](https://images-eureka.patsnap.com/patent_img/66cde1be-c9f1-46e3-8ce4-c16dca9408f8/BDA0001578978310000051.png "Theanine, [gamma]-aminobutyric acid and anthocyanin containing composition for relieving visual fatigue")
![Theanine, [gamma]-aminobutyric acid and anthocyanin containing composition for relieving visual fatigue](https://images-eureka.patsnap.com/patent_img/66cde1be-c9f1-46e3-8ce4-c16dca9408f8/BDA0001578978310000052.png "Theanine, [gamma]-aminobutyric acid and anthocyanin containing composition for relieving visual fatigue")
![Theanine, [gamma]-aminobutyric acid and anthocyanin containing composition for relieving visual fatigue](https://images-eureka.patsnap.com/patent_img/66cde1be-c9f1-46e3-8ce4-c16dca9408f8/BDA0001578978310000061.png "Theanine, [gamma]-aminobutyric acid and anthocyanin containing composition for relieving visual fatigue")
Owner:成都图径生物科技有限公司
Visual fatigue-alleviating composition containing Chinese wolfberry, chrysanthemum, gamma-aminobutyric acid and theanine
InactiveCN108261472AImprove neurological symptomsSignificant effect in alleviating visual fatigueSenses disorderHydroxy compound active ingredientsMental nerveGamma-Aminobutyric acid
Belonging to the field of medical health, the invention relates to a visual fatigue-alleviating composition containing Chinese wolfberry, chrysanthemum, gamma-aminobutyric acid and theanine. The invention provides the visual fatigue-alleviating composition, and the active ingredients include Chinese wolfberry, chrysanthemum, gamma-aminobutyric acid and theanine. The population trial result indicates that the composition provided by the invention is not only directed at the local symptoms of visual fatigue eyes, but also can obviously improve the neuropsychiatric symptoms caused by different degrees of visual fatigue, like inattention, memory deterioration and the like, has significant visual fatigue-alleviating effect, and has broad market prospects.
Owner:成都图径生物科技有限公司
Composition containing wolfberry fruit, chrysanthemum flower and theanine for relieving asthenopia
InactiveCN108057074AImprove neurological symptomsSignificant effect in alleviating visual fatigueSenses disorderNervous disorderMental nerveChrysanthemum Flower
The invention discloses a composition containing wolfberry fruit, chrysanthemum flower and theanine for relieving asthenopia, and belongs to the field of the healthy medicine. The invention provides the composition for reliving asthenopia, and active ingredients thereof are prepared from wolfberry fruit, chrysanthemum flower and theanine. The trial result of the people shows that the composition not only aims at asthenopia eye local symptom, but also can obviously improve the psychoneural symptom caused by asthenopia in different degrees, such as attention-deficit disorder and memory deterioration; the effect of relieving the asthenopia is obvious, and the extensive market prospect is provided.
Owner:成都图径生物科技有限公司
Application of theanine in preparing food, health products or medicines for relieving eye fatigue
InactiveCN108185440AImprove neurological symptomsSignificant effect in alleviating visual fatigueOrganic active ingredientsSenses disorderMental nerveActive component
The invention relates to application of theanine in preparing food, health products or medicines for relieving eye fatigue, and belongs to the field of medicine and health. One of the technical schemes of the invention provides the application of the theanine in preparing the food, health products or medicines for relieving eye fatigue. In addition, the invention also provides a composition for relieving eye fatigue, and the active components of the composition comprise theanine and anthocyanin. Shown by trial results of people, the composition provided by the invention aims at local symptomsof eye fatigue, can obviously improve psychosomatic manifestations such as aprosexia and memory decline caused by varying degrees of eye fatigue, has an obvious effect of relieving eye fatigue and hasbroad market prospects.
Owner:成都图径生物科技有限公司
A kind of traditional Chinese medicine preparation for treating women's climacteric syndrome
ActiveCN103933477BRaises Estradiol LevelsRelieve diastolic symptomsSexual disorderPlant ingredientsSalvia miltiorrhizaVasomotor symptom
The invention discloses a traditional Chinese medicine preparation for treating climacteric syndrome of women. The preparation is prepared from raw materials and auxiliary materials. The raw materials comprise the following components in parts by weight: 31-40 parts of cibotium barometz, 25-35 parts of salvia miltiorrhiza, 18-24 parts of curcuma zedoary, 18-24 parts of trifid sopubia herb, 15-25 parts of telegraph plants, 25-33 parts of habenaria dentate, 32-46 parts of fried spina date seed and 12-20 parts of angelica sinensis. The traditional Chinese medicine preparation disclosed by the invention can effectively improve the level of estradiol of women with climacteric syndrome and alleviate vasomotor symptom, autonomic imbalance and psychosomatic manifestations.
Owner:广东泰康制药有限公司
Composition containing fructus lycii, flos chrysanthemi, phosphatidylserine and theanine for relieving visual fatigue
InactiveCN108159188AImprove neurological symptomsSignificant effect in alleviating visual fatigueOrganic active ingredientsSenses disorderMental nerveAdditive ingredient
The invention relates to a composition containing fructus lycii, flos chrysanthemi, phosphatidylserine and theanine for relieving visual fatigue, and belongs to the field of medicine and health. The invention provides the composition for relieving visual fatigue, which is prepared from the active ingredients: the fructus lycii, the flos chrysanthemi, the phosphatidylserine and the theanine. The test result shows that the composition provided by the invention not only aims at visual fatigue eye local symptoms but also can remarkably improve psychosomatic manifestations such as inattention and memory deterioration caused by different degrees of visual fatigue, the composition has a remarkable effect on relieving visual fatigue, and has a broad market prospect.
Owner:成都图径生物科技有限公司
Traditional Chinese medicine preparation for treating climacteric syndrome of women
ActiveCN103933477ARaises Estradiol LevelsRelieve diastolic symptomsSexual disorderPlant ingredientsVasomotor symptomSalvia miltiorrhiza
The invention discloses a traditional Chinese medicine preparation for treating climacteric syndrome of women. The preparation is prepared from raw materials and auxiliary materials. The raw materials comprise the following components in parts by weight: 31-40 parts of cibotium barometz, 25-35 parts of salvia miltiorrhiza, 18-24 parts of curcuma zedoary, 18-24 parts of trifid sopubia herb, 15-25 parts of telegraph plants, 25-33 parts of habenaria dentate, 32-46 parts of fried spina date seed and 12-20 parts of angelica sinensis. The traditional Chinese medicine preparation disclosed by the invention can effectively improve the level of estradiol of women with climacteric syndrome and alleviate vasomotor symptom, autonomic imbalance and psychosomatic manifestations.
Owner:广东泰康制药有限公司
Remedies for psychoneurosis
A therapeutic drug for psychoneurotic disorders, which is useful for therapies of psychoneurotic disorders, especially restless legs syndrome is disclosed. The therapeutic drug for psychoneurotic disorders according to the present invention comprises as an effective ingredient an opioid kappa receptor agonist compound (excluding pentazocine) such as (-)-17-(cyclopropylmethyl)-3,14beta-dihydroxy-4,5alpha-epoxy-6beta[N-methyl-trans-3-(3-furyl)acrylamide]morphinan hydrochloric acid salt.
Owner:TORAY IND INC
Medicinal application of resveratrol
InactiveCN105267186AImproves the function of the hypothalamic-pituitary-thyroid axisImprove depression-related behaviorsNervous disorderHydroxy compound active ingredientsMental nerveSevere hypothyroidism
The invention discloses application of resveratrol to preparing medicines for treating sub-clinical hypothyroidism and neuropsychiatric syndromes due to the sub-clinical hypothyroidism. The application has the advantages that the resveratrol is applied to preparing the medicines for treating the sub-clinical hypothyroidism and the neuropsychiatric syndromes due to the sub-clinical hypothyroidism, accordingly, imbalance hypothalamus-pituitary-thyroid axis functions of sub-clinical hypothyroidism patients can be improved, the learning and memory ability of the sub-clinical hypothyroidism patients can be enhanced, and depression-related behavior of the sub-clinical hypothyroidism can be improved.
Owner:ANHUI MEDICAL UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com